Activity Overview
This educational activity is an archive of the live conference held from February 26, 2026, through February 28, 2026.
Target Audience
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
- Interpret the latest guidelines and evidence for the use of biomarker-driven strategies to stratify risk and select appropriate therapies for patients with hematologic disorders
- Describe best practices for mitigating and managing treatment-related adverse events in patients with hematologic disorders
Naval G. Daver, MD
Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer
Medicine
The University of Texas MD Anderson Cancer
Center
Houston, TX
Elias Jabbour, MD
Professor, Department of Leukemia
Division of Cancer Medicine
The University
Aaron C. Logan, MD, PhD, MPhil
Professor of Clinical Medicine
Director, Hematologic Malignancies Tissue
Bank
Hematology, Blood & Marrow Transplant,
and Cellular Therapy Program
University of California, San Francisco
San Francisco, CA
Bijal Shah, MD, MS
Associate Member, Department of Malignant
Hematology
Moffitt Cancer Center
Tampa, FL
Please click here to view disclosures for faculty and the staff of Physicians’ Education Resource®.